About Lycia Therapeutics
Lycia Therapeutics is a company based in San Francisco (United States) founded in 2020 by Carolyn Bertozzi. Lycia Therapeutics has raised $226.66 million across 3 funding rounds from investors including Lilly, ARE and Marshall Wace. The company has 22 employees as of December 31, 2021. Lycia Therapeutics offers products and services including LYTAC Platform and LYTAC Degraders. Lycia Therapeutics operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter San Francisco, United States
- Employees 22 as on 31 Dec, 2021
- Founders Carolyn Bertozzi
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lycia Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$226.66 M (USD)
in 3 rounds
-
Latest Funding Round
$106.6 M (USD), Series C
Apr 26, 2024
-
Investors
Lilly
& 9 more
-
Employee Count
22
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lycia Therapeutics
Lycia Therapeutics offers a comprehensive portfolio of products and services, including LYTAC Platform and LYTAC Degraders.
Enables development of degraders for eliminating disease-causing proteins.
Custom therapeutics to reduce levels of pathogenic proteins in diseases.
People of Lycia Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Lycia Therapeutics
Lycia Therapeutics has successfully raised a total of $226.66M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $106.6 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lycia Therapeutics
Lycia Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, ARE and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
VC & PE firm focused on healthcare sector
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Lycia Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lycia Therapeutics
Investment portfolio details for Lycia Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lycia Therapeutics
Detailed financials for Lycia Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lycia Therapeutics Comparisons
Peer comparison for Lycia Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lycia Therapeutics
Lycia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Lycia Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lycia Therapeutics
Complete news archive for Lycia Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lycia Therapeutics
Lycia Therapeutics was founded in 2020.
Lycia Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Lycia Therapeutics is a funded company, having raised a total of $226.66M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Lycia Therapeutics is 22.
Lycia Therapeutics was founded in 2020 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where targeted protein degradation technologies are advanced to address cancer and autoimmune diseases. The company, led by founder Carolyn Bertozzi, conducts research and development activities aimed at creating novel therapeutics. Efforts are centered on preclinical and clinical-stage programs in this specialized field.
Lycia Therapeutics's top competitors include Moderna, argenx and Forge Biologics.
Lycia Therapeutics offers LYTAC Platform and LYTAC Degraders.
Lycia Therapeutics has 10 investors. Key investors include Lilly, ARE, Marshall Wace, Franklin Templeton, and Janus Henderson Investors.